Aug. 28, 2024 |
|
Aug. 28, 2024 |
|
jRCT2031240303 |
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (J5I-OX-JZYA) |
|
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (J5I-OX-JZYA) |
Masaki Takeshi |
||
Eli Lilly Japan K.K. |
||
5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo |
||
+81-120-023-812 |
||
LTG_CallCenter@lists.lilly.com |
||
Trial Guide Call Center |
||
Eli Lilly Japan K.K. |
||
5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo |
||
+81-120-023-812 |
||
LTG_CallCenter@lists.lilly.com |
Pending |
Sept. 30, 2024 |
||
220 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
uncontrolled control |
||
parallel assignment |
||
treatment purpose |
||
Have one of the following solid tumor cancers: |
||
Individual with known or suspected uncontrolled CNS metastases |
||
18age old over | ||
No limit | ||
Both |
||
Metastatic Solid Tumor |
||
DRUG: LY4052031 |
||
Phase 1a: To determine the recommended phase 2 dose (RP2D) or optimal dose of LY4052031 [ Time Frame: Cycle 1 (21 Days)] |
||
Eli Lilly Japan K.K. |
Cancer Institute Hospital of JFCR IRB | |
3-8-31, Ariake, Koto-ku, Tokyo, Tokyo | |
+81-3-3520-0111 |
|
Tiken_office@ml.jfcr.or.jp | |
No |
|
NCT06465069 | |
ClinicalTrial.gov |
United States |